Abstract:Osteoporosis is induced by an imbalance between osteogenesis and bone resorption, and is treated with osteogenic drugs and/or resorption inhibitors. Resorption inhibitors, such as bisphosphonates, are orally used; however, orally active small molecules with osteogenic activity are not clinically available. We synthesized various types of small molecules and identified a series of diphenylamine and diphenylether derivatives that promoted osteoblast differentiation. Among them, diphenylether derivatives 13a, 13g, and 13h potently promoted osteoblast differentiation (EC200 for increasing alkaline phosphatase activity = 11.3, 31.1, and 12.3 nM, respectively) and inhibited cyclin-dependent kinase 8 (CDK8) activity (IC50 = 2.5, 7.8, and 3.9 nM, respectively), suggesting that their osteoblastgenic effects are mediated by the inhibition of CDK8. The ratio of the maximal plasma concentration after oral administration at 10 mg/kg in female rats and EC200 for osteoblastogenesis was 148.1 for compound 13a, 53.4 for 13g, and 101.8 for 13h, indicating possible in vivo osteoblastogenic and osteogenic effects. In ovariectomized female rats, 13g and 13h at 10 mg/kg/d for 8 weeks increased plasma bone-type alkaline phosphatase activity, indicating enhanced in vivo osteoblastogenesis. Furthermore, micro-computed tomography (micro-CT) showed that both compounds increased femoral cortical bone volume and mineral contents, which were unaffected by ovariectomy, while having negligible effects on trabecular bone volume and mineral contents, which were markedly reduced by ovariectomy. In conclusion, diphenylamine and diphenylether structures are novel scaffolds for osteoblastogenesis enhancers via the inhibition of CDK8. Among them, 13g and 13h are candidates for anti-osteoporotic drugs with cortical bone-selective osteogenic effects.

Novel Bone-Targeted Agents for Treatment of Osteoporosis

Research and Application of Target Therapy for Osteoporosis

A Novel Anti-Osteoporotic Agent That Protects Against Postmenopausal Bone Loss by Regulating Bone Formation and Bone Resorption.

Bisphosphonate‐enoxacin Inhibit Osteoclast Formation and Function by Abrogating RANKL‐induced JNK Signalling Pathways During Osteoporosis Treatment

A Mixture of Cervus elaphus sibiricus and Glycine max (L.) Merrill Inhibits Ovariectomy-Induced Bone Loss Via Regulation of Osteogenic Molecules in a Mouse Model

Raloxifene inhibits bone loss and improves bone strength through an Opg-independent mechanism

Synthesis and Biological Evaluation of Novel Bisphosphonates with Dual Activities on Bone in Vitro

A novel β-catenin-binding drug SAHPA1 in treatment of osteoporosis in ovariectomized mice

Engineered Plant Virus Complexes with a RANK Motif Modulator and Bone Targeting for Osteoporosis Treatment.

Recent Developments in Bone Anabolic Therapy for Osteoporosis

Targeted Delivery of Anti-Osteoporosis Therapy: Bisphosphonate-modified Nanosystems and Composites

A p38 MAP kinase inhibitor suppresses osteoclastogenesis and alleviates ovariectomy-induced bone loss through the inhibition of bone turnover

Technetium-99 Conjugated with Methylene Diphosphonate Ameliorates Ovariectomy-Induced Osteoporotic Phenotype Without Causing Osteonecrosis in the Jaw

Progress in Anti-Osteoporosis Drug Treatment

Bone-Targeted Biomimetic Nanogels Re-Establish Osteoblast/Osteoclast Balance to Treat Postmenopausal Osteoporosis

Synthesis and Evaluation of a Novel Series of Diphenylamine and Diphenylether Derivatives with Osteoblastogenic and Osteogenic Effects via CDK8 Inhibition

Novel Pyrazole Derivatives Effectively Inhibit Osteoclastogenesis, a Potential Target for Treating Osteoporosis

Prevention of alveolar bone loss in an osteoporotic animal model via interference of semaphorin 4d.

Targeting Bortezomib to Bone Increases Its Bone Anabolic Activity and Reduces Systemic Adverse Effects in Mice

Novel heterocyclic ring-fused oleanolic acid derivatives as osteoclast inhibitors for osteoporosis

Bone targeting antioxidative nano-iron oxide for treating postmenopausal osteoporosis